Case number 1:23-cv-01420
Harmony Biosciences, LLC et al v. MSN Pharmaceuticals Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 15, 2024 | N/A | Case associated with lead case: Create association to 1:23-cv-01286-JLH. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 1:23-cv-01286-JLH ONLY. (ceg) (Entered: 04/15/2024) (0) |
| Apr 15, 2024 | 31 | SCHEDULING AND CONSOLIDATION ORDER: Harmony Biosciences, LLC et al. v. Lupin Limited et al., C.A. No. 23-1286-JLH, Harmony Biosciences, LLC et al. v. AET Pharma US, Inc. et al., C.A. No. 23-1340-JLH, and Harmony Biosciences, LLC et al. v. MSN Pharms. Inc. et al., C.A. No. 23-1420-JLH, are consolidated for all purposes up to and including trial. Joinder of Parties due by 8/30/2024. Amended Pleadings due by 8/30/2024. Joint Claim Construction Brief due by 1/8/2025. A Markman Hearing is set for 3/27/2025 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. Interim Status Report due by 4/2/2025. Fact Discovery completed by 4/18/2025. Expert Discovery completed by 10/30/2025. Proposed Pretrial Order due by 1/14/2026. A Pretrial Conference is set for 1/21/2026 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. A 4-day Bench Trial is set for 2/17/2026 at 09:30 AM in Courtroom 6D before Judge Jennifer L. Hall. (*See Order for details). Signed by Judge Jennifer L. Hall on 4/15/2024. Associated Cases: 1:23-cv-01286-JLH, 1:23-cv-01340-JLH, 1:23-cv-01420-JLH(ceg) (Entered: 04/15/2024) (17) |
| Apr 8, 2024 | 30 | Joint PROPOSED Scheduling and Order re (23 in 1:23-cv-01420-JLH), (36 in 1:23-cv-01340-JLH), (27 in 1:23-cv-01286-JLH) Order, by Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche. (Attachments: # 1 Cover Letter to the Honorable Jennifer L. Hall)(Tigan, Jeremy) Modified on 4/8/2024 (ceg). (Entered: 04/08/2024) (0) |
| Apr 5, 2024 | 29 | NOTICE of Withdrawal of Motion by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. re 9 MOTION to Dismiss Based upon Under the First to File Rule (Weinblatt, Richard) (Entered: 04/05/2024) (2) |
| Apr 5, 2024 | 28 | SO ORDERED, re (44 in 1:23-cv-01340-JLH, 29 in 1:23-cv-01286-JLH, 27 in 1:23-cv-01420-JLH) Stipulation and Order to Extend Time for the parties to file a joint proposed scheduling order and letter to April 8, 2024. Signed by Judge Jennifer L. Hall on 4/5/2024. Associated Cases: 1:23-cv-01286-JLH, 1:23-cv-01340-JLH, 1:23-cv-01420-JLH(ceg) (Entered: 04/05/2024) (3) |
| Apr 4, 2024 | 27 | STIPULATION TO EXTEND TIME for the parties to file a joint proposed scheduling order and letter pursuant to the Court's Oral Orders (C.A. No. 23-1286, D.I. 27; C.A. No. 23-1340, D.I. 36; C.A. No. 23-1420, D.I. 23) to April 8, 2024 - filed by Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche. (Tigan, Jeremy) (Entered: 04/04/2024) (3) |
| Mar 21, 2024 | 26 | ANSWER to 21 Answer to Complaint, Counterclaim by Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC.(Tigan, Jeremy) (Entered: 03/21/2024) (15) |
| Mar 12, 2024 | 25 | SO ORDERED, re (41 in 1:23-cv-01340-JLH, 24 in 1:23-cv-01420-JLH) Stipulation and Order to Extend Time for the parties to file a proposed scheduling order and letter to April 4, 2024. Signed by Judge Jennifer L. Hall on 3/12/2024. Associated Cases: 1:23-cv-01340-JLH, 1:23-cv-01420-JLH(ceg) (Entered: 03/12/2024) (3) |
| Mar 12, 2024 | 24 | STIPULATION TO EXTEND TIME for the parties to file a proposed scheduling order and letter pursuant to the Court's Oral Orders (C.A. No. 23-1340, D.I. 36; C.A. No. 23-1420, D.I. 23) to April 4, 2024 - filed by Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche. (Tigan, Jeremy) (Entered: 03/12/2024) (3) |
| Mar 4, 2024 | 23 | ORAL ORDER: IT IS HEREBY ORDERED that, within thirty days, the parties shall jointly prepare and file the following: (i) a proposed Scheduling Order consistent with Judge Hall's "Rule 16 Scheduling Order - Patent", and (ii) a letter, not to exceed three pages, setting forth (a) the parties' positions regarding any disputes in the proposed Scheduling Order and (b) a list of any other issues the parties want to address at the Rule 16 Scheduling Conference. Thereafter, the Court may schedule a Rule 16 Scheduling Conference to be held with Judge Hall. The Scheduling Order can be found on Judge Hall's portion of the District Court's website. Ordered by Judge Jennifer L. Hall on 3/4/2024. (ceg) (Entered: 03/04/2024) (0) |
| Mar 1, 2024 | N/A | CORRECTING ENTRY: The pdf for the letter found at D.I. 22 has been replaced with a corrected version per counsel's request. (ceg) (Entered: 03/01/2024) (0) |
| Mar 1, 2024 | 22 | Letter to The Honorable Jennifer L. Hall from Richard C. Weinblatt regarding MSN's Petition for Writ of Mandamus Pertaining to Eastern District of Virginia Case. (Weinblatt, Richard) (Main Document 22 replaced on 3/1/2024) (ceg). (Entered: 03/01/2024) (1) |
| Feb 29, 2024 | 21 | ANSWER to 1 Complaint, , COUNTERCLAIM against Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 02/29/2024) (23) |
| Feb 2, 2024 | 20 | Letter to The Honorable Jennifer L. Hall from Jeremy A. Tigan regarding Joint Status Report. (Tigan, Jeremy) Modified on 2/2/2024 (ceg). (Entered: 02/02/2024) (2) |
| Jan 19, 2024 | 19 | ORAL ORDER: Having reviewed the January 17, 2024 letter (No. 23-1420, D.I. 18), IT IS ORDERED that, on or before February 2, 2024, the parties shall meet and confer and file a joint status report regarding how the Court should proceed with these actions (including the pending Motion to Dismiss (No. 23-1420, D.I. 9)). Ordered by Judge Jennifer L. Hall on 1/19/2024. Associated Cases: 1:23-cv-01420-JLH, 1:24-cv-00048-JLH(ceg) (Entered: 01/19/2024) (0) |
| Jan 17, 2024 | 18 | Letter to The Honorable Jennifer L. Hall from Jeremy A. Tigan regarding related action transferred from E.D. Va. (Attachments: # 1 Exhibit A)(Tigan, Jeremy) (Entered: 01/17/2024) (0) |
| Jan 11, 2024 | N/A | CORRECTING ENTRY: The pdf for the Reply Brief found at D.I. 17 has been replaced with a corrected version per counsel's request. (ceg) (Entered: 01/11/2024) (0) |
| Jan 10, 2024 | 17 | REPLY BRIEF re 9 MOTION to Dismiss Based upon Under the First to File Rule filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit I, # 2 Exhibit J, # 3 Exhibit K, # 4 Exhibit L, # 5 Exhibit M, # 6 Exhibit N, # 7 Exhibit O, # 8 Exhibit P, # 9 Exhibit Q, # 10 Exhibit R, # 11 Exhibit S, # 12 Exhibit T)(Weinblatt, Richard) (Main Document 17 replaced on 1/11/2024) (ceg). (Entered: 01/10/2024) (0) |
| Jan 9, 2024 | N/A | Pro Hac Vice Attorneys Ronald M. Daignault and Richard Juang for MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 01/09/2024) (0) |
| Jan 9, 2024 | N/A | SO ORDERED re 15 MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. ORDERED by Judge Maryellen Noreika on 1/9/2024. (dlw) (Entered: 01/09/2024) (0) |
| Jan 9, 2024 | N/A | Case Reassigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. Associated Cases: 1:23-cv-01286-JLH, 1:23-cv-01340-JLH, 1:23-cv-01420-JLH (rjb) (Entered: 01/09/2024) (0) |
| Jan 8, 2024 | 16 | Pro Hac Vice Fee - Credit Card Payment received for Ronald M. Daignault and Richard Juang. ( re 15 MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang )( Payment of $ 100, receipt number ADEDC-4309449).(Weinblatt, Richard) (Entered: 01/08/2024) (0) |
| Jan 8, 2024 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 01/08/2024) (5) |
| Jan 5, 2024 | N/A | SO ORDERED re 14 STIPULATION TO EXTEND TIME to Answer the Complaint to February 29, 2024 (Set/Reset Answer Deadlines: MSN Laboratories Private Limited answer due 2/29/2024; MSN Pharmaceuticals Inc. answer due 2/29/2024). ORDERED by Judge Maryellen Noreika on 1/5/2024. (dlw) (Entered: 01/05/2024) (0) |
| Jan 4, 2024 | 14 | STIPULATION TO EXTEND TIME to Answer the Complaint to February 29, 2024 - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 01/04/2024) (1) |
| Jan 3, 2024 | 13 | ANSWERING BRIEF in Opposition re 9 MOTION to Dismiss Based upon Under the First to File Rule filed by Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC.Reply Brief due date per Local Rules is 1/10/2024. (Attachments: # 1 Ex. 1, # 2 Ex. 2)(Tigan, Jeremy) (Entered: 01/03/2024) (0) |
| Jan 2, 2024 | N/A | SO ORDERED re 12 MOTION for Pro Hac Vice Appearance of Attorney Christopher N. Sipes, Erica N. Andersen, Brianne Bharkhda, Sarahi Uribe, Elaine H. Nguyen, Pierre Anquetil and Yiye Fu of COVINGTON & BURLING LLP filed by Harmony Biosciences, LLC, Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche. ORDERED by Judge Maryellen Noreika on 1/2/2024. (dlw) (Entered: 01/02/2024) (0) |
| Dec 26, 2023 | 12 | MOTION for Pro Hac Vice Appearance of Attorney Christopher N. Sipes, Erica N. Andersen, Brianne Bharkhda, Sarahi Uribe, Elaine H. Nguyen, Pierre Anquetil and Yiye Fu of COVINGTON & BURLING LLP - filed by Bioprojet Pharma SAS, Bioprojet Socite Civile de Recherche, Harmony Biosciences, LLC. (Tigan, Jeremy) (Entered: 12/26/2023) (10) |
| Dec 21, 2023 | 11 | SUMMONS Returned Executed by Harmony Biosciences, LLC, Bioprojet Socite Civile de Recherche, Bioprojet Pharma SAS.MSN Laboratories Private Limited served on 12/15/2023, answer due 1/5/2024. (Blumenfeld, Jack) (Entered: 12/21/2023) (2) |
| Dec 19, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Pvt. Ltd. for MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 12/19/2023) (2) |
| Dec 19, 2023 | 9 | MOTION to Dismiss Based upon Under the First to File Rule - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Text of Proposed Order)(Weinblatt, Richard) (Entered: 12/19/2023) (0) |
| Dec 14, 2023 | 8 | SUMMONS Returned Executed by Harmony Biosciences, LLC, Bioprojet Socite Civile de Recherche, Bioprojet Pharma SAS.MSN Pharmaceuticals Inc. served on 12/14/2023, answer due 1/4/2024. (Blumenfeld, Jack) (Entered: 12/14/2023) (2) |
| Dec 13, 2023 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) (Entered: 12/13/2023) (0) |
| Dec 11, 2023 | 7 | Summons Issued as to MSN Laboratories Private Limited on 12/11/2023; MSN Pharmaceuticals Inc. on 12/11/2023. (Attachments: # 1 Summons Issued MSN Pharmaceuticals Inc.)(jfm) (Entered: 12/12/2023) (0) |
| Dec 11, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bioproject Societe Civile de Recherche for Bioprojet Pharma SAS filed by Bioprojet Pharma SAS, Bioprojet Socit Civile de Recherche. (jfm) (Entered: 12/12/2023) (2) |
| Dec 11, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Harmony Biosciences Holdings, Inc. for Harmony Biosciences, LLC filed by Harmony Biosciences, LLC. (jfm) (Entered: 12/12/2023) (2) |
| Dec 11, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,486,947 B2; 8,207,197 B2; 8,354,430 B2. (jfm) (Entered: 12/12/2023) (1) |
| Dec 11, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Plaintiffs are still investigating the date notice was received. Date of Expiration of Patent: U.S. Patent No. 8,486,947 expires on September 26, 2029; U.S. Patent No. 8,207,197 expires on March 7, 2030; U.S. Patent No. 8,354,430 expires on February 6, 2026.Thirty Month Stay Deadline: 2/14/2027. (jfm) (Entered: 12/12/2023) (1) |
| Dec 11, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 12/12/2023) (3) |
| Dec 11, 2023 | 1 | COMPLAINT FOR PATENT INFRINGEMENT filed against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. (Filing fee $ 405, receipt number ADEDC-4292296.) - filed by Harmony Biosciences, LLC, Bioprojet Socite Civile de Recherche, Bioprojet Pharma SAS. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(jfm). (Entered: 12/12/2023) (0) |
